Xiangya Hospital of Central South University
Changsha, Hunan, 410008, China
Location status: Recruiting
Location contact
Jifeng Guo, Ph.D.
CONTACT
Qiying Sun, Ph.D.
CONTACT
NCT Number: NCT03523104
The purpose of the Chinese PD-LRRK2 Registry(CPD-LRRK2R) is to develop a database of patients of Parkinson's disease with leucine-rich repeat kinase 2 (LRRK2) gene variants in mainland China.
Interested in participating?
Request InfoAll sexes
Observational
Changsha, Hunan, 410008, China
Location status: Recruiting
Jifeng Guo, Ph.D.
CONTACT
Qiying Sun, Ph.D.
CONTACT
Parkinson's disease (PD) is the second most common disorder among neurodegenerative diseases. LRRK2 missense mutations are the most common known genetic cause of PD. However, some polymorphisms of LRRK2 such as G2385R and R1628P can also affect the risk of developing PD. The investigators aim to establish a database of PD with LRRK2 variants and characterize the clinical manifestation of these patients in mainland China.
Method:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
-
Time frame: 10 years
Establish the database of Parkinson's disease with LRRK2 variants in mainland China.
Time frame: 10 years
Characterize the clinical feature in patients of Parkinson's disease with LRRK2 variants
Contact information is provided by the study sponsor or research team.
Beisha Tang, Ph.D.
CONTACT
Jifeng Guo, Ph.D.
CONTACT
Xiangya Hospital of Central South University
Other
The Chinese Parkinson's Disease With LRRK2 Variants Registry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07207122
Basal Ganglia Diseases, Brain Diseases
Santa Monica, California, United States
View Trial DetailsNCT06680830
Basal Ganglia Diseases, Brain Diseases
Sun City, Arizona, United States
View Trial DetailsNCT07323121
Basal Ganglia Diseases, Brain Diseases
Nanjing, Jiangsu, China
View Trial DetailsNCT04477785
Anosmia, Basal Ganglia Diseases
Birmingham, Alabama, United States
View Trial Details